Invest in

Drug-Patent Cliffs

21.1%
6.9%
0.0%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
21.1%
6.9%
0.0%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 19.1%
18.4% Taro Pharmaceutical Industries Ltd. TARO 0.8%
16.6% Dr. Reddy's Laboratories Ltd RDY 25.1%
14.6% Mylan N.V. MYL 18.4%
11.0% Sagent Pharmaceuticals Inc. SGNT 14.7%
10.2% Impax Laboratories Inc. IPXL 35.0%
8.9% Akorn Inc. AKRX 26.5%
5.7% Abbott Laboratories ABT 10.8%
4.1% Mallinckrodt plc MNK 45.1%
3.7% Lannett Co Inc LCI 47.3%
2.4% Sanofi American Depositary Shares (Each repstg one-half of one) SNY 15.6%
1.7% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 20.9%
1.3% Cambrex Corporation CBM 11.9%
1.1% The Medicines Company MDCO 25.7%
0.4% Endo International PLC ENDP 79.2%

Quotes delayed 15 mins. Currently Jul 30, 2016 5:11:47 AM. Fields are marked with -- when data is unavailable.